Cargando…
Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases
BACKGROUND: Malignant peritoneal mesothelioma (MPM) is a rare malignant tumor with a high mortality rate and extremely poor prognosis. In-depth pathological analysis is essential to assess tumor biological behaviors and explore potential therapeutic targets of MPM. Nucleoplasmin 2 (NPM2) is a molecu...
Autores principales: | Wu, He-liang, Yang, Zhi-ran, Su, Yan-dong, Ma, Ru, Du, Xue-mei, Gao, Ying, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590226/ https://www.ncbi.nlm.nih.gov/pubmed/36280841 http://dx.doi.org/10.1186/s12957-022-02811-y |
Ejemplares similares
-
NPM2 in malignant peritoneal mesothelioma: from basic tumor biology to clinical medicine
por: Wu, He-liang, et al.
Publicado: (2022) -
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
por: Yang, Zhi-Ran, et al.
Publicado: (2020) -
Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal
mesothelioma
por: Yang, Zhi-Ran, et al.
Publicado: (2021) -
Malignant Peritoneal Mesothelioma
por: Fukunaga, Tomohiko, et al.
Publicado: (2022) -
Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
por: Yang, Zhi-Ran, et al.
Publicado: (2022)